Goldman Sachs lowers Stoke Therapeutics price target on expenses

Goldman Sachs reduced Stoke Therapeutics' (STOK) price target to $43 from $44, maintaining a Buy rating. The company reported Q3 2026 operating expenses of $88.6M, higher than estimates. Revenue was $11.25M, exceeding expectations. The Phase 3 EMPEROR trial for zorevunersen is on track for a 2027 readout. STOK trades at $26.35 with a Strong Buy consensus.

Original reporting
Published Oct 30, 2026, 9:16 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 9:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$STOK
Bearish
high confidence
Mentioned
$STOK
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$STOKBearishMed
01

Why it matters

The analyst downgrade may trigger short‑term sell pressure, but the strong cash position and upcoming trial readout provide a longer‑term catalyst.

02

Market read

Primary relevance is the analyst price‑target cut following the earnings release, which may influence short‑term trading decisions for STOK.

03

What to watch

Potential upside from upcoming Phase 3 readout and NDA filing could offset short‑term expense concerns.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

Stoke Therapeutics (NASDAQ:STOK) disclosed Q3 2026 results, showing revenue beat but wider loss and higher operating costs. Goldman Sachs lowered its price target, maintaining a Buy rating.

Company-level read

Ticker impact

$STOKBearishHigh confidence
Context

Goldman Sachs cut its price target to $43 from $44 after Stoke Therapeutics reported Q3 results with higher-than-expected expenses and a mixed earnings beat.

Expected impact

likely pressure as the market prices in the lower target and expense concerns

Evidence & confidence

The price‑target reduction is a fresh analyst action on the same day as the earnings release, providing a clear, time‑sensitive signal.

Market effects

Biotech sector may see heightened scrutiny on expense management and trial timelines.

US biotech investors may adjust exposure to small‑cap clinical‑stage companies.

Limited; impact confined to Stoke Therapeutics and comparable micro‑cap biotech peers.

Counterpoint

Despite higher expenses, cash runway remains strong; the trial progress could justify a higher valuation.

Key entities

  • Goldman Sachs

    Provided the revised price target and rating.

  • Biogen

    Co‑developer of the EMPEROR trial for zorevunersen.

Related articles

$NOCMed

ULA’s Latest Launch Failure Spells Trouble for Space Force

United Launch Alliance's (ULA) Vulcan Centaur rocket failed during a Nov. 15 launch, destroying 40 Amazon satellites and tightening Space Force launch capacity. The issue was attributed to inadequate fuel supply to the BE-4 engines, built by Blue Origin. ULA faces further investigation, while SpaceX's successful Starship test cements its dominance.

$STOKMed

Stoke Therapeutics Q3 Earnings Call Highlights

Stoke Therapeutics (STOK) discussed Q3 earnings, highlighting plans for zorevunersen's NDA submission in 2027. The FDA supports a multicomponent endpoint for cognition/behavior. Stoke estimates 38,000 Dravet syndrome patients in key markets. STK-002 for ADOA is in Phase I trials. Q3 net loss was $73.6M, with $358.8M cash. Stoke expects funding into early 2028.

$STOKMed

Stoke Q3 2026 slides: EMPEROR trial advances with zero dropouts

Stoke Therapeutics (STOK) reported Q3 2026 progress, highlighting zero dropouts in its EMPEROR Phase 3 trial for zorevunersen in Dravet syndrome. The company beat revenue estimates but reported a wider-than-expected loss. Stoke has $358.8M in cash, enough to fund operations into early 2028. The trial enrolled 162 patients, exceeding the target, with strong patient retention and statistical significance in endpoints. The FDA has accepted the study's multicomponent approach for regulatory filing.

$STOKMed

Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Updates

Stoke Therapeutics, Inc. (STOK) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX 99.1 Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Updates –Phase 3 EMPEROR study of zorevunersen, an investigational medicine for Dravet syndrome: ~110 patients through Week 28 primary endpoint, ~20 patients through Week 52 and all co

$STOKMedAI 8/10

About 110 patients reached the seizure-measurement point in a Dravet drug trial

Stoke Therapeutics reported progress in its Phase 3 EMPEROR study for zorevunersen, an investigational drug for Dravet syndrome, with 110 patients reaching the Week 28 primary endpoint. The company plans to submit data to the FDA in the first half of 2027 and complete the NDA submission in the second half. Additionally, the Phase 1 OSPREY study for STK-002, targeting ADOA, is ongoing with initial data expected in H1 2027.

$STOKLow

Stoke Therapeutics presents data on ADOA treatment STK-002

Stoke Therapeutics (STOK) presented data on STK-002, an experimental treatment for Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology 2026 Annual Meeting. The Phase 1 OSPREY study completed dosing in the first two cohorts, with initial safety and efficacy data expected in 2027. STK-002 targets the OPA1 gene, which causes 65-90% of ADOA cases. The study aims to assess safety, tolerability, and visual function improvements.